Gyre Therapeutics, Inc. Detailed Financials

Full historical quarterly statements

Metric	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	22.5M	37.2M	30.6M	26.8M	22.1M	27.9M	25.5M	25.2M
Cost of Goods Sold	1.2M	1.7M	1.6M	1.2M	894K	1.2M	958K	770K
Gross Profit	21.3M	35.5M	28.9M	25.6M	21.2M	26.7M	24.5M	24.5M
R&D Expenses	6.7M	4.8M	2.4M	3.4M	3.1M	3.7M	2.8M	3.4M
Operating Expenses	30.6M	35.3M	22.0M	23.4M	18.9M	26.1M	20.3M	21.2M
Operating Income	-9.4M	120K	6.9M	2.2M	2.3M	597K	4.2M	3.3M
Other Income / Gains	118K	-186K	704K	67K	2.4M	175K	-303K	2.8M
Net Income	-8.6M	-1.7M	3.6M	442K	2.7M	-99K	1.1M	3.5M
EPS (Diluted)	-0.10	-0.019	0.04	0.005	0.03	-0.19	0.058	0.041
Reported Currency	USD	USD	USD	USD	USD	USD	USD	USD
Gross Profit Ratio	0.946	0.953	0.947	0.957	0.959	0.958	0.962	0.969
General And Administrative Expenses	7.2M	6.7M	4.3M	4.8M	5.0M	5.5M	3.8M	3.4M
Selling And Marketing Expenses	14.1M	23.8M	15.3M	15.2M	10.8M	16.9M	13.7M	14.4M
Selling General And Administrative Expenses	21.4M	30.5M	19.6M	20.0M	15.8M	22.3M	17.5M	17.8M
Other Expenses	2.6M	0	1K	1K	0	66K	0	0
Cost And Expenses	31.9M	37.1M	23.6M	24.6M	19.8M	27.3M	21.3M	22.0M
Interest Income	0	0	200K	300K	200K	346K	523K	350K
Interest Expense	0	0	0	0	0	0	0	0
Depreciation And Amortization	0	695K	649K	641K	535K	471K	474K	238K
Ebitda	-9.4M	815K	8.3M	2.8M	2.8M	1.1M	4.7M	3.5M
Ebitdaratio	-0.415	0.022	0.271	0.105	0.127	0.041	0.185	0.139
Operating Income Ratio	-0.415	0.003	0.227	0.081	0.103	0.021	0.166	0.129
Income Before Tax	-9.2M	-66K	7.6M	2.2M	4.6M	772K	3.9M	6.0M
Income Before Tax Ratio	-0.41	-0.002	0.25	0.084	0.21	0.028	0.154	0.239
Income Tax Expense	-621K	1.3M	1.7M	662K	901K	203K	1.1M	1.5M
Net Income Ratio	-0.383	-0.046	0.118	0.017	0.122	-0.004	0.044	0.14
Epsdiluted	-0.10	-0.017	0.035	0.002	0.004	-0.16	0.049	0.034
Weighted Average Shs Out	91.3M	91.2M	89.1M	89.1M	86.4M	85.1M	85.6M	85.5M
Weighted Average Shs Out Dil	91.3M	102.9M	102.7M	102.7M	102.0M	102.3M	102.6M	104.3M